Product information and disease descriptionProduct descriptionProduct informationPharmacology
Pharmacodynamics
18 evidence topics · 7 sources
Reduction of ESR1 variant mutations in circulating tumor DNA
Clinical benefit by change in ESR1 mutations
“In patients who had been treated with the RP2D of 120 mg/day palazestrant and had ctDNA available for analysis, the CBR was 73% (8/11) in patients who had a reduction in ESR1 mutations and 25% (8/32) in those who did not have a reduction in ESR1 mutations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ki67 and estrogen receptor expression in tumor samples
“Palazestrant treatment was associated with significantly reduced Ki67 levels from 29.2% (N = 18) to 20.4% (N = 12); P = 0.041” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“resulted in a numerical decrease in ERα Allred score from 6.67 (N = 18) to 5.17 (N = 12); P = 0.13” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Target engagement in a patient-derived xenograft
“OP-1250 reduced Ki67 levels in a dose-dependent manner, in line with observed tumor growth inhibition” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At both the 5 and 10 mg/kg doses, nuclear ERα staining was reduced by approximately 75%, compared with the vehicle group, confirming target engagement” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Uterine wet weight assay
“E2 and tamoxifen significantly increased UWW, while OP-1250 and fulvestrant did not. OP-1250 and fulvestrant inhibited E2-induced increases in weight, with OP-1250 displaying dose-dependent inhibition as low as 0.01 mg/kg” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ESR1 Y537S patient-derived xenografts
“In this model, OP-1250 doses of ≥1 mg/kg outperformed fulvestrant, and all treatments led to tumor growth inhibition; 10 and 30 mg/kg doses led to tumor shrinkage below starting volume in all treated animals” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Both OP-1250 doses outperformed elacestrant, with greatest tumor growth inhibition with 10 mg/kg OP-1250.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Intracranial xenograft model
“4 of 8 animals in the OP-1250 monotherapy group and 6 of 8 in the OP-1250 + ribociclib group lacked detectable tumor at study day 100.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“OP-1250 treatment (monotherapy or in combination with ribociclib) resulted in all 8 animals alive at study day 100 and 6 alive 50 days after cessation of dosing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Preclinical combination with CDK4/6 inhibitors
“The 10 mg/kg dose of OP-1250, which leads to plasma concentrations similar to those measured in clinical studies, outperformed 75 mg/kg monotherapy doses of both CDK4/6 inhibitors and resulted in tumor shrinkage. Combination treatment resulted in more pronounced and consistent tumor shrinkage across doses, with all but one animal achieving >50% reduction in tumor volume” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“addition of OP-1250 to either CDK4/6 inhibitor extended animal survival” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
QTcF in the phase 1/2 monotherapy study
Planned electrocardiogram analysis
Bradycardia at the recommended phase 2 dose
“TEAEs of oral SERDs observed in less than 10% of patients treated at the RP2D of palazestrant included bradycardia (9%) and photopsia (5%); all bradycardia and photopsia events were grade 1, and there were no dose modifications, interruptions, or discontinuations due to these events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote